Mycoplasma Testing Global Market Report 2024

The mycoplasma testing market size has grown rapidly in recent years. It will grow from $0.94 billion in 2023 to $1.08 billion in 2024 at a compound annual growth rate (CAGR) of 14.0%. The growth observed during the historical period can be attributed to outbreaks and contamination incidents, increased awareness, expansion in the biotechnology sector, research and development initiatives, evolving trends in the healthcare industry, and an increase in cell culture production.

The mycoplasma testing market size is expected to see rapid growth in the next few years. It will grow to $1.71 billion in 2028 at a compound annual growth rate (CAGR) of 12.2%. The anticipated growth in the forecast period can be attributed to the demand for quality assurance, emerging market demand, growth in the biopharmaceutical industry, an increase in cell-based therapies, and the continued expansion of the biotechnology sector. Major trends expected during this period include a focus on regulatory standards and compliance, increased awareness and diagnostics in healthcare, innovations in point-of-care testing, global pandemic preparedness, and market penetration in emerging economies.

The rising incidence of mycoplasma pneumonia is expected to drive the growth of the mycoplasma testing market in the foreseeable future. Mycoplasma pneumonia refers to a respiratory infection caused by the bacteria Mycoplasma pneumoniae. In the diagnostic landscape, mycoplasma testing holds a pivotal role in identifying this infection by detecting the presence of Mycoplasma pneumoniae bacteria in respiratory specimens. This aids in the timely and accurate diagnosis of the infection, facilitating appropriate medical treatment and management. As reported by the Centers for Disease Control and Prevention in December 2023, a US-based government agency, an estimated 2 million cases of Mycoplasma pneumoniae infections occur annually in the United States. This significant prevalence of mycoplasma pneumonia serves as a key factor propelling the growth of the mycoplasma testing market.

The increasing aging population is anticipated to drive the growth of the mycoplasma testing market in the coming years. The aging population represents a demographic shift marked by a higher proportion or a growing number of individuals aged 65 and older within a society. In this context, mycoplasma testing becomes crucial for the early detection and management of respiratory infections among the elderly. Timely and targeted treatment facilitated by mycoplasma testing contributes to safeguarding the health of older individuals. As reported by the World Health Organization in October 2022, a US-based specialized health agency, the global demographic trend indicates that 1 in 6 individuals will be 60 or older by 2030, and the elderly population is expected to reach 2.1 billion by 2050. This substantial increase in the aging population is a key factor propelling the growth of the mycoplasma testing market.

Major players in the mycoplasma testing market are actively engaging in strategic investments, including the launch of innovative products, research and development advancements, and technological innovations, to gain prominence in the industry. Companies recognize the importance of introducing novel products to meet the evolving needs of end-users and expand their consumer base in the competitive business landscape. As an illustration, in October 2022, SwiftDx, a UK-based biotechnology company, introduced a new mycoplasma contamination detection test using a polymerase chain reaction (PCR)-based method. The SwiftDx Mycoplasma Detection Kit is a lateral flow test that provides a rapid and accurate means of detecting mycoplasma. The test efficiently utilizes a small sample directly from the cell culture media supernatant without disrupting cell growth. The results are presented in a simple and easy-to-read format. Notably, the test demonstrates high sensitivity and specificity, boasting a detection limit of less than 10 colony-forming units per milliliter (cfu/mL) after day 3 of culture. This example exemplifies the industry's commitment to staying competitive by investing in cutting-edge technologies and delivering innovative solutions to address the dynamic requirements of mycoplasma testing.

Major companies in the mycoplasma testing market are intensifying their focus on the introduction of digital PCR kits as a strategic move to gain a competitive edge. Digital PCR kits are molecular biology tools that employ a digital approach for the precise quantification and analysis of nucleic acids, such as DNA or RNA. As an example, in November 2023, QIAGEN, a Germany-based diagnostics company, unveiled three new QIAcuity digital PCR kits along with updated software to enhance the application of digital PCR in biopharmaceutical research and food safety. The QIAcuity kits are meticulously designed to ensure precise quantification and are available in one, four, and eight-plate versions. The one-plate version is particularly noteworthy as it can process up to 384 samples in an eight-hour shift. Among the new kits launched, the QIAcuity Mycoplasma Quant Kit stands out, offering researchers an accurate and precise means to detect mycoplasma contaminants at various stages of research. This strategic emphasis on digital PCR kits reflects the industry's commitment to leveraging advanced technologies for enhanced accuracy and efficiency in mycoplasma testing, meeting the evolving needs of the market.

In December 2021, Asahi Kasei Medical, a pharmaceutical company based in Japan, completed the acquisition of Bionique Testing Laboratories LLC for an undisclosed sum. The strategic intent behind this acquisition was to strengthen Asahi Kasei Medical's biosafety testing services, a segment initiated in 2019 through the acquisition of ViruSure, a viral safety testing services provider in Austria. Bionique Testing Laboratories LLC, situated in the United States, specializes in mycoplasma testing services for the biotherapeutics and life sciences industries. The acquisition further reinforces Asahi Kasei Medical's commitment to providing comprehensive biosafety solutions and expanding its capabilities in serving the evolving needs of the pharmaceutical sector.

Major companies operating in the mycoplasma testing market report are Abbott Laboratories, Merck KGaA, Thermo Fisher Scientific Inc., Boston Scientific Corporation, Olympus Corporation, Agilent Technologies Inc., Lonza Group AG, Roche Diagnostics International AG, Smith & Nephew plc, Charles River Laboratories International Inc., CONMED Corporation, Nelson Laboratories Fairfield Inc., AngioDynamics Inc., Creative Bioarray, Biological Industries Israel Beit Haemek Ltd., Biotools B & M Labs S.A, PromoCell GmbH, American Type Culture Collection, Bionique Testing Laboratories Inc., InvivoGen, Clongen Laboratories LLC, Norgen Biotek Corporation, Gen Bio Sciences (P) Ltd., GeneCopoeia Inc., Minerva Biolabs GmbH, Mycoplasma Experience, Savyon Diagnostics, ScienCell Research Laboratories Inc., AtriCure Inc., Advanced Cardiac Therapeutics Inc., ARTWORKSIT.

North America was the largest region in the mycoplasma testing market in 2023. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the mycoplasma testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the mycoplasma testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Various mycoplasma testing technologies include polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA), enzymatic methods, and deoxyribonucleic acid (DNA) staining. PCR utilizes specific primers for mycoplasma DNA, typically targeting mycoplasma 16S rRNA genes. ELISA detects mycoplasma presence through antibodies or labeled probes for the mycoplasma 16S rRNA genes. Enzymatic methods involve converting ADP to ATP using mycoplasmal enzymes in a suspected cell culture sample. DNA staining identifies M. hyorhinis by growing samples with Vero cells and using a fluorescent dye for DNA staining. Mycoplasma testing products encompass instruments, assays, kits, and reagents. Widely applied in cell line, virus, and end-of-production testing, it serves pharmaceutical and biotechnology companies, cell banks and laboratories, contract research organizations, and academic research institutes.

The mycoplasma testing market research report is one of a series of new reports that provides mycoplasma testing market statistics, including mycoplasma testing industry global market size, regional shares, competitors with mycoplasma testing market share, detailed mycoplasma testing market segments, market trends and opportunities, and any further data you may need to thrive in the mycoplasma testing industry. This mycoplasma testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The mycoplasma testing market includes revenues earned by entities by PCR detection assay, indirect hoechst stain, and culture isolation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.